Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Biohaven completed enrollment in the pivotal RISE3 study evaluating Opakalim for refractory focal epilepsy, with top-line results expected in the second half of 2026. Interim data from an open-label extension study demonstrated that 54% of participants on the 75 mg dose achieved a 50% or greater reduction in seizure frequency, alongside a favorable tolerability profile with low rates of nervous system adverse events.
Key figures
- Drug Name
- Opakalim (BHV-7000)
- Phase Of Trial
- Phase 2/3
- Ole rollover rate
- ~95%
- Ole responder rate
- 54%
- Adverse event fatigue
- 4%
- Adverse event dizziness
- 5%
- Double blind completion rate
- ~95%
- Participants studied to date
- >1,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.